Notably, the first OV-based therapy approved for the treatment of melanoma in the USA in 2015 delivered the human GM-CSF for enhanced immune response, so this immune stimulator proved itself as a reliable therapeutic, albeit not 100% effective. Here, CSF2 is linked to melanoma.